---
title: e.l.f. Beauty (ELF) — Wall Street analysts' targets, grades and estimates
canonical: https://sweetvaluelab.com/stocks/elf/analysts
ticker: ELF
as_of: 2026-11-02
sector: Consumer Defensive
---
# e.l.f. Beauty (ELF) — Wall Street analysts

10 firms published a price target for ELF in the last 90 days. Counting each firm once, at its latest, the median target is $110.50, 1% below the last close of $111.69 (Oct 30, 2026); the lowest is $65.00 and the highest $127.00.

These are the analysts' figures, quoted, not this site's. The site's own model value for ELF is on the valuation page: https://sweetvaluelab.com/stocks/elf/valuation.

## At a glance

| Figure | Value |
| --- | ---: |
| Median target (each firm's latest, last 90 days) | $110.50 |
| Median target vs last close | −1% |
| Firms with a target, last 90 days | 10 |
| Lowest – highest target | $65.00 – $127.00 |
| Current grades of 16 firms: positive / neutral / negative | 11 / 5 / 0 |
| Upgrades / downgrades, last 12 months | 1 / 2 |
| Consensus revenue growth, next 3 fiscal years | +13% a year |

## Each firm's latest target (last 90 days)

Newest first. Change is against the same firm's previous target; the last two columns are the target against the close on the day it was published and against the last close.

| Date | Firm | Target | Previous | Change | Vs price then | Vs price now | Report |
| --- | --- | ---: | ---: | ---: | ---: | ---: | --- |
| 2026-10-21 | Deutsche Bank | $105.00 | $64.00 | +64% | −9% | −6% | https://thefly.com/ajax/news_get.php?id=4445922 |
| 2026-10-15 | UBS | $116.00 | $80.00 | +45% | +2% | +4% | https://thefly.com/ajax/news_get.php?id=4442445 |
| 2026-10-15 | Morgan Stanley | $103.00 | $59.00 | +75% | −7% | −8% | https://thefly.com/ajax/news_get.php?id=4442339 |
| 2026-10-07 | Baird | $120.00 | $105.00 | +14% | +17% | +7% | https://thefly.com/ajax/news_get.php?id=4437144 |
| 2026-10-01 | Raymond James | $117.00 | $87.00 | +34% | +14% | +5% | https://thefly.com/ajax/news_get.php?id=4434096 |
| 2026-09-17 | Bernstein | $127.00 | $121.00 | +5% | +36% | +14% | https://thefly.com/ajax/news_get.php?id=4427039 |
| 2026-08-27 | Canaccord Genuity | $123.00 | $110.00 | +12% | +15% | +10% | https://thefly.com/ajax/news_get.php?id=4417386 |
| 2026-08-06 | Piper Sandler | $65.00 | $50.00 | +30% | −32% | −42% | https://thefly.com/ajax/news_get.php?id=4404580 |
| 2026-08-06 | B. Riley | $100.00 | — | — | +16% | −10% | https://www.streetinsider.com/Analyst+Comments/e.l.f.+Beauty+%28ELF%29+PT+Raised+to+%24100+at+B.Riley/26877161.html |
| 2026-08-06 | Goldman Sachs | $100.00 | $95.00 | +5% | +16% | −10% | https://www.streetinsider.com/Analyst+Comments/e.l.f.+Beauty+%28ELF%29+PT+Raised+to+%24100+at+Goldman+Sachs/26876943.html |

## Current grades (each firm's latest, last 12 months)

| As of | Firm | Grade |
| --- | --- | --- |
| 2026-10-22 | Canaccord Genuity | “Buy” |
| 2026-10-19 | Jefferies | “Buy” |
| 2026-10-19 | J.P. Morgan | “Overweight” |
| 2026-10-15 | Morgan Stanley | “Equal Weight” |
| 2026-10-14 | Citigroup | “Buy” |
| 2026-10-07 | Baird | “Outperform” |
| 2026-10-01 | Raymond James | “Strong Buy” |
| 2026-09-17 | Bernstein | “Outperform” |
| 2026-09-16 | B. Riley | “Buy” |
| 2026-09-15 | Bank of America | “Buy” |
| 2026-08-10 | TD Cowen | “Buy” |
| 2026-08-06 | UBS | “Neutral” |
| 2026-08-06 | Piper Sandler | “Neutral” |
| 2026-08-06 | Evercore ISI | “In Line” |
| 2026-03-30 | Deutsche Bank | “Hold” |
| 2025-11-07 | Goldman Sachs | “Buy” |

## Grade changes (last 24 months)

| Date | Firm | From | To | Action |
| --- | --- | --- | --- | --- |
| 2026-08-05 | Bernstein | “Market Perform” | “Outperform” | upgrade |
| 2026-05-01 | Morgan Stanley | “Overweight” | “Equal Weight” | downgrade |
| 2025-11-06 | Piper Sandler | “Overweight” | “Neutral” | downgrade |
| 2025-09-02 | Deutsche Bank | “Buy” | “Hold” | downgrade |
| 2025-08-11 | Morgan Stanley | “Equal Weight” | “Overweight” | upgrade |
| 2025-02-07 | D.A. Davidson | “Buy” | “Neutral” | downgrade |
| 2025-02-07 | Morgan Stanley | “Overweight” | “Equal Weight” | downgrade |
| 2025-02-07 | UBS | “Buy” | “Neutral” | downgrade |
| 2025-01-13 | Morgan Stanley | “Equal Weight” | “Overweight” | upgrade |

32 older changes are listed on the page.

## Consensus estimates by fiscal year

A reported year shows the company's revenue and GAAP diluted EPS with the consensus beside it; a later year shows the consensus average and its range. The analysts' EPS usually leaves items such as stock compensation out, so reported and estimated EPS are not like for like.

| Fiscal year | Status | Revenue | YoY | EPS | YoY | Consensus revenue | Consensus EPS | Analysts |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| 2024 | reported | $1.0B | +77% | $2.21 | +99% | $995.4M (reported +3% vs it) | $2.98 | 12 |
| 2025 | reported | $1.3B | +28% | $1.92 | −13% | $1.3B (reported 0% vs it) | $3.33 | 14 |
| 2026 | reported | $1.6B | +25% | $0.44 | −77% | $1.6B (reported +2% vs it) | $3.10 | 15 |
| 2027 | estimate | $2.0B | +21% | $3.67 | +18% | $2.0B – $2.0B | $3.54 – $3.83 | 15 |
| 2028 | estimate | $2.2B | +9% | $3.94 | +7% | $2.1B – $2.2B | $3.34 – $4.21 | 14 |
| 2029 | estimate | $2.4B | +10% | $4.54 | +15% | $2.3B – $2.4B | $4.39 – $4.68 | 6 |
| 2030 | estimate | $2.5B | +5% | $5.23 | +15% | $2.4B – $2.6B | $5.05 – $5.40 | 3 |
| 2031 | estimate | $2.7B | +9% | $5.80 | +11% | $2.6B – $2.8B | $5.61 – $5.98 | 2 |

---

Source: https://sweetvaluelab.com/stocks/elf/analysts (SweetValueLab, free, no account). Targets, grades and estimates are the analysts' own, quoted from Financial Modeling Prep's analyst feeds; reported figures from the company's statements. Research and educational data, not investment advice; nothing here is a recommendation to buy, sell or hold any security.